AUS
NZ
UK
CA
USA
IND
Healt
Percheron Therapeutics (ASX:PER) Moves Closer to Phase II Trials
October 31, 2025 12:47 PM AEDT| By SamPercheron Therapeutics (ASX:PER) showcases strong clinical momentum with its anti-VISTA antibody program, positioning itself for the next phase of cancer research advancement.
Ansell Limited (ASX:ANN) Gains Momentum Amid Weak Financial Outlook
October 30, 2025 04:20 PM AEDT| By SamAnsell Limited (ASX:ANN) gains traction amid industrial market recovery, facing scrutiny over its financial strength and long-term adaptability in a competitive ASX environment.
Cochlear and JB Hi-Fi Among Key ASX 200 Stocks to Watch
October 30, 2025 03:43 PM AEDT| By SamCochlear and JB Hi-Fi continue to influence the ASX 200 landscape through innovation, resilience, and consistent growth across healthcare and retail sectors in Australia’s stock market.
Healthcare Stocks on the ASX 200 Gain Attention Amid Sector Revival
October 30, 2025 03:07 PM AEDT| By SamASX healthcare stocks are regaining momentum as key players like CSL and ResMed lead innovations across biotechnology and medical imaging, supported by global demand and strategic international partnerships.
Doctor Care Anywhere Group (ASX:DOC) Faces Market Pressure Amid Shifting Healthcare Trends
October 29, 2025 05:09 PM AEDT| By SamDoctor Care Anywhere Group (ASX:DOC) experiences renewed market scrutiny amid Australia’s evolving healthcare landscape, reflecting shifting investor expectations and sector-wide digital transformation.
Cryosite Limited (ASX:CTE) Shows Steady Growth Momentum in the ASX Stock Market
October 29, 2025 05:05 PM AEDT| By SamCryosite Limited (ASX:CTE) continues to strengthen its market presence with operational excellence and steady growth momentum in Australia’s evolving ASX landscape.
ASX 200 Midday Update: Materials Gain While Healthcare Faces Pressure
October 29, 2025 02:21 PM AEDT| By SamMaterials stocks advanced while healthcare struggled during midday trade, shaping a mixed session for the ASX 200. The divergence highlighted shifting investor sentiment across key Australian market sectors.
CSL (ASX:CSL) Shares Hit Multi-Year Low Amid Revised Growth Outlook
October 28, 2025 05:43 PM AEDT| By SamCSL (ASX:CSL) adjusts its multi-year growth forecast, prompting investor scrutiny and renewed attention to the healthcare sector within the ASX 200 index.
CSL Vaccine Setback Jolts ASX Healthcare Stocks
October 28, 2025 04:51 PM AEDT| By SamThe article explores CSL Limited’s (ASX:CSL) vaccine challenges and their impact on the broader ASX healthcare landscape, while examining what’s next for Australia’s leading biotech giant.
CSL (ASX:CSL) Faces Guidance Revision Amid US Vaccination Decline
October 28, 2025 03:32 PM AEDT| By SamCSL (ASX:CSL) revises guidance amid lower US vaccination rates and delays its Seqirus demerger, signalling broader strategic recalibration across the ASX healthcare landscape.
CSL Ltd (ASX:CSL): Assessing True Value in Today’s Market
October 27, 2025 04:57 PM AEDT| By SamExplore how CSL Ltd (ASX:CSL) shapes investor confidence in the ASX stock market with insights into its business fundamentals and long-term growth potential.
Vitasora Health (ASX:VHL) Expands US via Evolent Care
October 24, 2025 02:08 PM AEDT| By SamVitasora Health expands its US operations through an enhanced partnership with Evolent Care, aiming to scale Connected Care services nationwide and strengthen its path to profitability.
FDA Fast Track for NNZ-2591: Boost for Neuren (ASX:NEU)?
October 23, 2025 02:41 PM AEDT| By SamNeuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track for NNZ-2591, highlighting potential regulatory acceleration, clinical progress, and implications for the ASX stock market and short selling trends.
Explore ResMed (ASX:RMD) in the Dynamic ASX Stock Market
October 23, 2025 02:27 PM AEDT| By SamIn-depth look at ResMed (ASX:RMD) in the ASX stock market, highlighting healthcare innovation, sector stability, and investment trends.
Lumos Diagnostics (ASX:LDX) Speeds Up US Expansion
October 23, 2025 01:00 PM AEDT| By SamLumos Diagnostics (ASX:LDX) strengthens US market momentum with FebriDx® rollout, regulatory progress, and strategic service-driven innovation.
CSL & Pro Medicus Ltd Insights: Key ASX Stocks Worth Watching
October 22, 2025 06:17 PM AEDT| By SamA deep dive into CSL (ASX:CSL) and Pro Medicus Ltd (ASX:PME), highlighting their operations, market trends, and position in the ASX stock market.
CSL & Pro Medicus: Health Giants Under the ASX 200 Spotlight
October 22, 2025 06:01 PM AEDT| By SamCSL Ltd (ASX:CSL) and Pro Medicus Ltd (ASX:PME) drive innovation across biotechnology and digital healthcare, reinforcing Australia’s leadership within the ASX 200 through science, technology, and sustainable growth.
BlinkLab (ASX:BB1) Launches Dx 1 for Neuro Diagnostics
October 22, 2025 03:07 PM AEDT| By SamBlinkLab (ASX:BB1) advances child neurodevelopment diagnostics with Dx 1, demonstrating high accuracy and preparing for FDA trials.
Compumedics Limited’s Growth Story Sparks Market Attention
October 17, 2025 06:36 PM AEDT| By SamCompumedics Limited (ASX:CMP) gains investor focus as its innovation-driven growth story unfolds within Australia’s evolving medical technology landscape, reflecting broader optimism across the healthcare and diagnostic sectors.
Doctor Care Anywhere (ASX:DOC) Moves Toward Profitability Milestone
October 17, 2025 05:41 PM AEDT| By SamDoctor Care Anywhere (ASX:DOC) advances in digital healthcare, narrowing losses and nearing profitability, reflecting growing confidence in technology-driven medical services within the evolving ASX-listed healthcare landscape.
Advertise your brand on Kalkine Media